EUCTR2006-002499-16-IT进行中（未招募）不适用
Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options. - ND
TIBOTEC PHARMACEUTICALS LTD.0 个研究点目标入组 5,000 人开始时间: 2007年6月14日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who meet all of the following criteria are eligible for this trial. 1. Subject or Legal Authorized Representative has voluntarily given informed consent before initiation of trial procedures. 2. Subject has documented HIV-1 infection. 3. Male or female subject over 18 years of age. 4. Subject has limited treatment options due to virological failure or intolerance to multiple ARV regimens. 5. Subject is at least 3-class experienced (3 classes of licensed oral ARVs: N[t]RTIs, PIs, NNRTIs). Note: Subjects with primary NNRTI resistance can be included if they are experienced with at least 2 classes of ARVs (PIs, N[t]RTIs) and meet all the other inclusion criteria. 6. Subject has previously received 2 different PI-based regimens. 7. Subject is unable to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance. 8. Subject, if currently receiving an ARV regimen, is not achieving adequate virologic suppression on his/her current regimen (defined as a confirmed detectable plasma VL on the current treatment).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting one or more of the following criteria cannot be selected. 1. Primary HIV infection. 2. Prior or current participation in DUET trials (TMC125-C206 or TMC125-C216). 3. Any condition (including but not limited to alcohol and drug use), which, in the opinion of the investigator, could compromise the subject?s safety or adherence to the protocol. 4. Use of disallowed concomitant therapy, including disallowed ARVs (See Section 5.3.8.2). 5.Use of non-ARV investigational medications within the 30 days prior to baseline visit. 6. Use of investigational ARVs, unless stated as an exception in Section 5.3.8.2.2. 7. Any active clinically significant disease (e.g., cardiac dysfunction, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that is not either resolved or stabilized for at least 30 days before the screening phase of the trial. 8. Acute viral hepatitis, including but not restricted to A, B or C. 9. Pregnant or breast-feeding female. 10. Female subject of childbearing potential not using effective non-hormonal birth control methods or not willing to continue practicing these birth control methods from screening until the last trial related activity. 11. Subjects with the following laboratory abnormalities as defined by a standardized grading scheme based on the Division of AIDS (DAIDS) grading table (updated version from December 2004, see Section 7.2): - Hemoglobin < 7.4 g/dL (4.5 mmol/L) - Absolute neutrophil count < 500/mm? (0.500 x 109/L) - Platelets <25,000/mm3 (25.000 x 109/L) - Prothrombin time (PT) >1.50 x upper limit of laboratory normal range (ULN) Note: Subjects on anticoagulant therapy with elevated PT >1.5 ULN require approval of the sponsor prior to enrollment. - Alkaline phosphatase >5 x ULN - Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) >5 x ULN Bilirubin > 5 x ULN Note: Subjects with elevated bilirubin >5xULN assessed as related to a component of ART therapy may be enrolled with prior approval of the sponsor. - Lipase >3 x ULN - Amylase >5 x ULN if lipase >2 x ULN - Creatinine >1.8 x ULN 12. Subjects with clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels. 13.Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication (TMC125).
研究者
相似试验
进行中（未招募）
不适用
未命名试验EUCTR2006-002499-16-DEJanssen R&D Ireland
已完成
不适用
Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.HIV-110047438NL-OMON30522Janssen-Cilag120
进行中（未招募）
1 期
TMC207TBC3001 - Early Access of TMC207 in Patients with Extensively Drug Resistant (XDR) or Pre-XDR Pulmonary Tuberculosis (TB)Tuberculosis (TB)MedDRA version: 14.1Level: PTClassification code 10044755Term: TuberculosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-021125-12-LTJanssen Infectious Diseases BVBA295
Approved For Marketing
3 期
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral DrugsHIV-1NCT00354627Tibotec Pharmaceuticals, Ireland5,178
进行中（未招募）
不适用
Early access of TMC114 in combination with low-dose ritonavir RTV and other antiretrovirals ARVs in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. - TMC114-C226EUCTR2005-002437-13-ITTIBOTEC PHARMACEUTICALS LTD.15,000